FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2562187931> ?p ?o ?g. }

• W2562187931 endingPage "68" @default.
• W2562187931 startingPage "58" @default.
• W2562187931 abstract "Parkinson’s Disease (PD) is a chronic neurodegenerative disorder characterized by motor deficits which result from the progressive loss of dopaminergic neurons. Gene therapy using growth factors such as VEGF seems to be a viable approach for potential therapeutic treatment of PD. In this study, we utilized a novel non-viral gene carrier designated as PEI-PLL synthesized by our laboratory to deliver VEGF gene to study its effect by using both cell culture as well as animal models of PD. For cell culture experiments, we utilized 6-hydroxydopamine (6-OHDA) mediated cell death model of MN9D cells following transfection with either a control plasmid or VEGF expressing plasmid. As compared to control transfected cells, PEI-PLL mediated VEGF gene delivery to MN9D cells resulted in increased cell viability, increase in the number of Tyrosine hydroxylase (TH) positive cells and decreased apoptosis following 6-OHDA insult. Next, we studied the therapeutic potential of PEI-PLL mediated VEGF gene delivery in SNPc by using unilateral 6-OHDA Medial forebrain bundle (MFB) lesion model of PD in rats. VEGF administration prevented the loss of motor functions induced by 6-OHDA as determined by behavior analysis. Similarly, VEGF inhibited the 6-OHDA mediated loss of DA neurons in Substantia Nigra Pars Compacta (SNPc) as well as DA nerve fibers in striatum as determined by TH immunostaining. In addition, PEI-PLL mediated VEGF gene delivery also prevented apoptosis and microglial activation in PD rat models. Together, these results clearly demonstrated the beneficial effects of PEI-PLL mediated VEGF gene delivery on dopaminergic system in both cell culture and animal models of PD. In this report, we exploited the potential of PEI-PLL to deliver VEGF gene for the potential therapeutic treatment of PD by using both cell culture and animal models of PD. To the best of our knowledge, this is the first report describing the use of novel polymeric gene carriers for the delivery of VEGF gene to DA neurons with improved transfection efficiency. Finally, the study will lead to a significant advancement in the field of non-viral PD gene therapy treatment." @default.
• W2562187931 created "2017-01-06" @default.
• W2562187931 creator A5009514201 @default.
• W2562187931 creator A5011673154 @default.
• W2562187931 creator A5043992437 @default.
• W2562187931 creator A5045930233 @default.
• W2562187931 creator A5059247859 @default.
• W2562187931 creator A5078494506 @default.
• W2562187931 creator A5080628068 @default.
• W2562187931 date "2017-05-01" @default.
• W2562187931 modified "2023-10-17" @default.
• W2562187931 title "Polylysine-modified polyethylenimine (PEI-PLL) mediated VEGF gene delivery protects dopaminergic neurons in cell culture and in rat models of Parkinson's Disease (PD)" @default.
• W2562187931 cites W1513780852 @default.
• W2562187931 cites W1965379481 @default.
• W2562187931 cites W1970949369 @default.
• W2562187931 cites W1973897139 @default.
• W2562187931 cites W1974074671 @default.
• W2562187931 cites W1974752045 @default.
• W2562187931 cites W1985091985 @default.
• W2562187931 cites W1987522740 @default.
• W2562187931 cites W1990441398 @default.
• W2562187931 cites W1994583626 @default.
• W2562187931 cites W1996001296 @default.
• W2562187931 cites W1998880668 @default.
• W2562187931 cites W1999156699 @default.
• W2562187931 cites W2000292756 @default.
• W2562187931 cites W2002836409 @default.
• W2562187931 cites W2002917813 @default.
• W2562187931 cites W2008017799 @default.
• W2562187931 cites W2009348400 @default.
• W2562187931 cites W2015629481 @default.
• W2562187931 cites W2022155997 @default.
• W2562187931 cites W2022971351 @default.
• W2562187931 cites W2025585496 @default.
• W2562187931 cites W2025857959 @default.
• W2562187931 cites W2037457942 @default.
• W2562187931 cites W2039114029 @default.
• W2562187931 cites W2044164680 @default.
• W2562187931 cites W2048292311 @default.
• W2562187931 cites W2053184316 @default.
• W2562187931 cites W2053272214 @default.
• W2562187931 cites W2059278874 @default.
• W2562187931 cites W2090295661 @default.
• W2562187931 cites W2094846662 @default.
• W2562187931 cites W2095073588 @default.
• W2562187931 cites W2116174761 @default.
• W2562187931 cites W2120412053 @default.
• W2562187931 cites W2126714051 @default.
• W2562187931 cites W2133230336 @default.
• W2562187931 cites W2134845552 @default.
• W2562187931 cites W2139086927 @default.
• W2562187931 cites W2143058635 @default.
• W2562187931 cites W2168605004 @default.
• W2562187931 cites W2203444202 @default.
• W2562187931 cites W2317364432 @default.
• W2562187931 cites W2412195237 @default.
• W2562187931 doi "https://doi.org/10.1016/j.actbio.2016.12.048" @default.
• W2562187931 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28025049" @default.
• W2562187931 hasPublicationYear "2017" @default.
• W2562187931 type Work @default.
• W2562187931 sameAs 2562187931 @default.
• W2562187931 citedByCount "34" @default.
• W2562187931 countsByYear W25621879312017 @default.
• W2562187931 countsByYear W25621879312018 @default.
• W2562187931 countsByYear W25621879312019 @default.
• W2562187931 countsByYear W25621879312020 @default.
• W2562187931 countsByYear W25621879312021 @default.
• W2562187931 countsByYear W25621879312022 @default.
• W2562187931 countsByYear W25621879312023 @default.
• W2562187931 crossrefType "journal-article" @default.
• W2562187931 hasAuthorship W2562187931A5009514201 @default.
• W2562187931 hasAuthorship W2562187931A5011673154 @default.
• W2562187931 hasAuthorship W2562187931A5043992437 @default.
• W2562187931 hasAuthorship W2562187931A5045930233 @default.
• W2562187931 hasAuthorship W2562187931A5059247859 @default.
• W2562187931 hasAuthorship W2562187931A5078494506 @default.
• W2562187931 hasAuthorship W2562187931A5080628068 @default.
• W2562187931 hasConcept C135983454 @default.
• W2562187931 hasConcept C137183658 @default.
• W2562187931 hasConcept C159167319 @default.
• W2562187931 hasConcept C169760540 @default.
• W2562187931 hasConcept C2776773494 @default.
• W2562187931 hasConcept C2780938664 @default.
• W2562187931 hasConcept C502942594 @default.
• W2562187931 hasConcept C513476851 @default.
• W2562187931 hasConcept C54009773 @default.
• W2562187931 hasConcept C54355233 @default.
• W2562187931 hasConcept C81885089 @default.
• W2562187931 hasConcept C86803240 @default.
• W2562187931 hasConcept C95444343 @default.
• W2562187931 hasConcept C98274493 @default.
• W2562187931 hasConceptScore W2562187931C135983454 @default.
• W2562187931 hasConceptScore W2562187931C137183658 @default.
• W2562187931 hasConceptScore W2562187931C159167319 @default.
• W2562187931 hasConceptScore W2562187931C169760540 @default.
• W2562187931 hasConceptScore W2562187931C2776773494 @default.
• W2562187931 hasConceptScore W2562187931C2780938664 @default.
• W2562187931 hasConceptScore W2562187931C502942594 @default.

• next